XIIDRA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xiidra, and when can generic versions of Xiidra launch?
Xiidra is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and fifty-four patent family members in twenty-five countries.
The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this compound. Additional details are available on the lifitegrast profile page.
DrugPatentWatch® Generic Entry Outlook for Xiidra
Xiidra was eligible for patent challenges on July 11, 2020.
There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There is one tentative approval for the generic drug (lifitegrast), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XIIDRA?
- What are the global sales for XIIDRA?
- What is Average Wholesale Price for XIIDRA?
Summary for XIIDRA
International Patents: | 154 |
US Patents: | 11 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 12 |
Patent Applications: | 267 |
Drug Prices: | Drug price information for XIIDRA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for XIIDRA |
What excipients (inactive ingredients) are in XIIDRA? | XIIDRA excipients list |
DailyMed Link: | XIIDRA at DailyMed |


Recent Clinical Trials for XIIDRA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Novartis Pharmaceuticals | Phase 4 |
State University of New York College of Optometry | Phase 4 |
Bucci Laser Vision Institute | Phase 4 |
Pharmacology for XIIDRA
Drug Class | Lymphocyte Function-Associated Antigen-1 Antagonist |
Mechanism of Action | Lymphocyte Function-Associated Antigen-1 Antagonists |
Paragraph IV (Patent) Challenges for XIIDRA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
XIIDRA | Ophthalmic Solution | lifitegrast | 5% | 208073 | 4 | 2020-07-13 |
US Patents and Regulatory Information for XIIDRA
XIIDRA is protected by eleven US patents.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XIIDRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Try for Free | ⤷ Try for Free |
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Try for Free | ⤷ Try for Free |
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Try for Free | ⤷ Try for Free |
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Try for Free | ⤷ Try for Free |
Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | ⤷ Try for Free | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XIIDRA
When does loss-of-exclusivity occur for XIIDRA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08317473
Patent: Compositions and methods for treatment of diabetic retinopathy
Estimated Expiration: ⤷ Try for Free
Canada
Patent: 02984
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Try for Free
Patent: 58665
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Try for Free
Patent: 05972
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Try for Free
China
Patent: 1873797
Patent: Compositions and methods for treatment of diabetic retinopathy
Estimated Expiration: ⤷ Try for Free
Patent: 2056485
Patent: Topical LFA-1 antagonists for use in localized treatment of immune related disorders
Estimated Expiration: ⤷ Try for Free
Patent: 2065694
Patent: Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
Estimated Expiration: ⤷ Try for Free
Patent: 2065893
Patent: Delivery of LFA-1 antagonists to the gastrointestinal system
Estimated Expiration: ⤷ Try for Free
Patent: 5943534
Patent: 用于局部治疗免疫相关疾病的局部LFA-1拮抗剂 (Topical LFA-1 antagonists for use in localized treatment of immune related disorders)
Estimated Expiration: ⤷ Try for Free
European Patent Office
Patent: 09371
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Try for Free
Patent: 65124
Patent: ANTAGONISTES DE LFA-1 SOUS FORME D'AÉROSOL UTILISÉS EN TRAITEMENT LOCALISÉ DE TROUBLES DE NATURE IMMUNITAIRE (AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Try for Free
Patent: 65125
Patent: ANTAGONISTES DE LFA-1 TOPIQUES UTILISÉS DANS LE TRAITEMENT LOCALISÉ DE TROUBLES DE NATURE IMMUNITAIRE (TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Try for Free
Patent: 76508
Patent: ADMINISTRATION D'ANTAGONISTES DE LFA-1 AU SYSTÈME GASTRO-INTESTINAL (DELIVERY OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Try for Free
Patent: 67886
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'OEDÈME MACULAIRE (COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA)
Estimated Expiration: ⤷ Try for Free
Patent: 32444
Patent: ANTAGONISTES LFA-1 TOPIQUES POUR UNE UTILISATION DANS LE TRAITEMENT LOCALISÉ DE TROUBLES IMMUNITAIRES ASSOCIÉS (TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Try for Free
Patent: 97775
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Try for Free
Japan
Patent: 08037
Estimated Expiration: ⤷ Try for Free
Patent: 11500683
Estimated Expiration: ⤷ Try for Free
Patent: 11516607
Estimated Expiration: ⤷ Try for Free
Patent: 11518155
Estimated Expiration: ⤷ Try for Free
Patent: 11521896
Estimated Expiration: ⤷ Try for Free
Patent: 14132032
Patent: TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
Estimated Expiration: ⤷ Try for Free
Patent: 14132033
Patent: AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
Estimated Expiration: ⤷ Try for Free
Patent: 14133751
Patent: DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM
Estimated Expiration: ⤷ Try for Free
Patent: 14221808
Patent: 糖尿病性網膜症の治療のための組成物及び方法 (COMPOSITION AND METHOD FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷ Try for Free
Patent: 16128515
Patent: 免疫関連障害の局所治療に使用するためのエアゾール化LFA−1アンタゴニスト (AEROSOLIZED LFA-1 ANTAGONIST TO BE USED FOR TOPICAL TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Try for Free
Patent: 16153432
Patent: 胃腸系へのLFA−1アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Try for Free
Patent: 17141310
Patent: 免疫関連障害の局所治療に使用するためのエアゾール化LFA−1アンタゴニスト (AEROSOLIZED LFA-1 ANTAGONIST TO BE USED FOR TOPICAL TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷ Try for Free
Patent: 18127485
Patent: 胃腸系へのLFA−1アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Try for Free
Patent: 20023546
Patent: 胃腸系へのLFA−1アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷ Try for Free
Mexico
Patent: 10004281
Patent: COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE LA RETINOPATIA DIABETICA. (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY.)
Estimated Expiration: ⤷ Try for Free
Spain
Patent: 30406
Estimated Expiration: ⤷ Try for Free
Patent: 63703
Estimated Expiration: ⤷ Try for Free
Patent: 30024
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering XIIDRA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2544678 | MODULATORS OF CELLULAR ADHESION | ⤷ Try for Free |
Denmark | 1881823 | ⤷ Try for Free | |
European Patent Office | 1881823 | COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DES TROUBLES OCULAIRES (COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS) | ⤷ Try for Free |
World Intellectual Property Organization (WIPO) | 2005044817 | ⤷ Try for Free | |
World Intellectual Property Organization (WIPO) | 2014100135 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XIIDRA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2444079 | C02444079/01 | Switzerland | ⤷ Try for Free | FORMER OWNER: NOVARTIS AG, CH |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Xiidra
More… ↓